Nichole T. Tanner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nichole T. Tanner has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
Gerard A. Silvestri
Thoracic Oncology Research Group, Charleston, SC; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC
23 shared publications- Gerard A. Silvestri
Thoracic Oncology Research Group, Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina
20 shared publications - Peter J. Mazzone
Cleveland Clinic, Cleveland, Ohio
14 shared publications - Aakanksha Rangnekar
Delfi Diagnostics, Baltimore, Maryland
12 shared publications Alessandro Leal
12 shared publications- Ali Hussainy Zaidi
Allegheny Health Network Cancer Institute, Allegheny Health Network, Pittsburgh, USA
12 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Elsevier in CHEST Pulmonary
A great idea but a big lift”: Clinician and administrator experience with implementation of a mobile lung cancer screening program
- 18 November 2026
- Published by Elsevier in CHEST Pulmonary
Open AccessA great idea but a big lift”: Clinician and administrator experience with implementation of a mobile lung cancer screening program
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S5 and S6 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
Whole genome cfDNA analyses. Clinical and demographic characteristics of individuals analyzed.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S5 and S6 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
Whole genome cfDNA analyses. Clinical and demographic characteristics of individuals analyzed.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supp Figs (Fig S1-4) and Tables (Tables S1-4) from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
Cross-validated test; DELFI score distribution; Annual transitions.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupp Figs (Fig S1-4) and Tables (Tables S1-4) from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
Cross-validated test; DELFI score distribution; Annual transitions.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
Performance of blood-based lung cancer screening test. A, Sensitivity and specificity of the test in the clinical validation set (N = 382) overall and by clinical subgroup. Point estimates are reported with 95% Wilson confidence intervals. Overall sensitivity and specificity denoted by solid vertical lines. B, Sensitivity of the test in the lung cancer cases in the clinical validation set (N = 248) evaluated across cancer histology, and T, N, and M categories. Point estimates are reported with 95% Wilson confidence intervals. Overall sensitivity of 84% denoted by the solid horizontal line. C, Left, sensitivity of the test in the lung cancer cases in the clinical validation set (N = 246) by cancer group stage. Middle, bar plot showing the stage distribution of lung cancer as observed in populations undergoing lung cancer screening with LDCT (based on NLST study) that are used to weigh observed stage-specific sensitivities. Right, lung cancer screening relevant stage-weighted sensitivity in clinical validation set. D, Comparison of the NNS with LDCT conditioned on test positive or negative result when applied in the lung cancer screening eligible population. Test performance showed consistency across clinical subgroups and expected increased performance with increasing burden of disease (tumor (T), node (N), metastasis (M) and group staging). After weighting, the stage distribution to reflect a screening population, test performance remained high and demonstrated the ability to reliably identify those individuals more likely to have lung cancer detected on LDCT.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
Performance of blood-based lung cancer screening test. A, Sensitivity and specificity of the test in the clinical validation set (N = 382) overall and by clinical subgroup. Point estimates are reported with 95% Wilson confidence intervals. Overall sensitivity and specificity denoted by solid vertical lines. B, Sensitivity of the test in the lung cancer cases in the clinical validation set (N = 248) evaluated across cancer histology, and T, N, and M categories. Point estimates are reported with 95% Wilson confidence intervals. Overall sensitivity of 84% denoted by the solid horizontal line. C, Left, sensitivity of the test in the lung cancer cases in the clinical validation set (N = 246) by cancer group stage. Middle, bar plot showing the stage distribution of lung cancer as observed in populations undergoing lung cancer screening with LDCT (based on NLST study) that are used to weigh observed stage-specific sensitivities. Right, lung cancer screening relevant stage-weighted sensitivity in clinical validation set. D, Comparison of the NNS with LDCT conditioned on test positive or negative result when applied in the lung cancer screening eligible population. Test performance showed consistency across clinical subgroups and expected increased performance with increasing burden of disease (tumor (T), node (N), metastasis (M) and group staging). After weighting, the stage distribution to reflect a screening population, test performance remained high and demonstrated the ability to reliably identify those individuals more likely to have lung cancer detected on LDCT.
- Open Access
- 1 March 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (3) , 436-451
Lung Cancer Screening and Incidental Findings: A Research Agenda: An Official American Thoracic Society Research Statement
Background: Lung cancer screening with low-dose computed tomography (LDCT) may uncover incidental findings (IFs) unrelated to lung cancer. There may be potential benefits from identifying clinically significant IFs that warrant intervention and potential harms related to identifying IFs that are not clinically significant but may result in additional evaluation, clinician effort, patient anxiety, complications, and excess cost. Objectives: To identify knowledge and research gaps and develop and prioritize research questions to address the approach to and management of IFs. Methods: We convened a multidisciplinary panel to review the available literature on IFs detected in lung cancer screening LDCT examinations, focusing on variability and standardizing reporting, management of IFs, and evaluation of the benefits and harms of IFs, particularly cardiovascular-related IFs. We used a three-round modified Delphi process to prioritize research questions. Results: This statement identifies knowledge gaps in 1) reporting of IFs, 2) management of IFs, and 3) identifying and reporting coronary artery calcification found on lung cancer screening LDCT. Finally, we present the panel’s initial 36 research questions and the final 20 prioritized questions. Conclusions: This statement provides a prioritized research agenda to further efforts focused on evaluating, managing, and increasing awareness of IFs in lung cancer screening.
- 1 March 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (3) , 436-451
Open AccessLung Cancer Screening and Incidental Findings: A Research Agenda: An Official American Thoracic Society Research Statement
Background: Lung cancer screening with low-dose computed tomography (LDCT) may uncover incidental findings (IFs) unrelated to lung cancer. There may be potential benefits from identifying clinically significant IFs that warrant intervention and potential harms related to identifying IFs that are not clinically significant but may result in additional evaluation, clinician effort, patient anxiety, complications, and excess cost. Objectives: To identify knowledge and research gaps and develop and prioritize research questions to address the approach to and management of IFs. Methods: We convened a multidisciplinary panel to review the available literature on IFs detected in lung cancer screening LDCT examinations, focusing on variability and standardizing reporting, management of IFs, and evaluation of the benefits and harms of IFs, particularly cardiovascular-related IFs. We used a three-round modified Delphi process to prioritize research questions. Results: This statement identifies knowledge gaps in 1) reporting of IFs, 2) management of IFs, and 3) identifying and reporting coronary artery calcification found on lung cancer screening LDCT. Finally, we present the panel’s initial 36 research questions and the final 20 prioritized questions. Conclusions: This statement provides a prioritized research agenda to further efforts focused on evaluating, managing, and increasing awareness of IFs in lung cancer screening.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Table 1 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
Participant demographics and clinical characteristics.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
Participant demographics and clinical characteristics.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Figure 3 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
High-dimensional fragmentation features reflect lung cancer biology and are incorporated in the machine learning classifier. A, Heatmap representation of the deviation of cfDNA fragmentation features across the genome for the classifier training set with lung cancer or noncancer individuals compared with the mean of classifier training noncancer individuals. Each row represents a sample, whereas columns show individual genomic features. The cross-validated DELFI score and clinical characteristics are indicated to the left of the fragmentation deviation heatmap. B, Left, TCGA-derived observations of chromosomal arm gains (red) and losses (blue) in lung adenocarcinoma (LUAD; n = 518) and squamous cell cancer tissues (LUSC; n = 501). Right, the observed chromosome arm gains (red) and losses (blue) in the classifier training individuals separated by histology. C, A heatmap representation of the principal component eigenvectors of the fragmentation profile features. Regression coefficients from the final classifier indicating how the principal components of the fragmentation profiles and z-scores of the chromosomal arms were combined are provided in the top and right margins of the heatmap, respectively. Positive values for the coefficients are represented in red, whereas negative values are represented in blue. Agreement across copy number chromosomal gains and losses in TCGA lung cancers, observed z-scores in the cfDNA of patients with lung cancer, and chromosome arm model coefficients reflect biologic consistency between chromosomal changes in lung cancer, cfDNA fragmentation profiles, and classifier features.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection
High-dimensional fragmentation features reflect lung cancer biology and are incorporated in the machine learning classifier. A, Heatmap representation of the deviation of cfDNA fragmentation features across the genome for the classifier training set with lung cancer or noncancer individuals compared with the mean of classifier training noncancer individuals. Each row represents a sample, whereas columns show individual genomic features. The cross-validated DELFI score and clinical characteristics are indicated to the left of the fragmentation deviation heatmap. B, Left, TCGA-derived observations of chromosomal arm gains (red) and losses (blue) in lung adenocarcinoma (LUAD; n = 518) and squamous cell cancer tissues (LUSC; n = 501). Right, the observed chromosome arm gains (red) and losses (blue) in the classifier training individuals separated by histology. C, A heatmap representation of the principal component eigenvectors of the fragmentation profile features. Regression coefficients from the final classifier indicating how the principal components of the fragmentation profiles and z-scores of the chromosomal arms were combined are provided in the top and right margins of the heatmap, respectively. Positive values for the coefficients are represented in red, whereas negative values are represented in blue. Agreement across copy number chromosomal gains and losses in TCGA lung cancers, observed z-scores in the cfDNA of patients with lung cancer, and chromosome arm model coefficients reflect biologic consistency between chromosomal changes in lung cancer, cfDNA fragmentation profiles, and classifier features.